By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


WuXi AppTec, Inc. 

101 Morgan Lane

Plainsboro  New Jersey  08536  U.S.A.
Phone: 609-606-6616 Fax: n/a


Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.

WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 14,000 employees and 6 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.

Key Statistics

Ownership: Private

Web Site: WuXi AppTec

Company News
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements In Decades On Cancer Treatments 8/10/2017 11:39:29 AM
WuXi AppTec Merges Formulation/Finishing Services Into API Manufacturing Division 8/1/2017 10:18:06 AM
WuXi AppTec's Pharmaceutical Development Services Division Merges With STA Pharmaceutical 7/31/2017 9:10:51 AM
WuXi AppTec Participates In $5.9 Million Series A For Rodeo Therapeutics 7/26/2017 11:26:12 AM
WuXi AppTec Completes Acquisition Of HD Biosciences Co., Ltd 5/15/2017 8:04:37 AM
WuXi AppTec Plans China IPO 3/28/2017 9:44:57 AM
WuXi AppTec Lab Testing Division's Bioanalytical Service Unit Passed FDA Inspection 3/1/2017 8:20:32 AM
WuXi AppTec's STA Pharmaceutical To Expand Changzhou Site 2/3/2017 12:13:24 PM
WuXi AppTec Release: Company Acquires Biology Focused R&D Service Leader HD Biosciences Co., Ltd 1/19/2017 11:11:26 AM
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017 7:57:01 AM